Skip to main content

Table 1 Patient characteristics and observed pathological complete response (pCR)

From: Predictive and prognostic value of Matrix metalloproteinase (MMP) - 9 in neoadjuvant chemotherapy for triple-negative breast cancer patients

Characteristics Number of patients Number of pCR (%) Chi-squared test P value Multivariate P value
Age    0.564 NS
  < 40 60 23 (38.3)   
 40–59 194 66 (34.0)   
 60+ 49 14 (28.6)   
Menopausal status    0.817 NS
 Pre 159 55 (34.6)   
 Post 144 48 (33.3)   
Tumor size at baseline    0.026 0.030
 T2 150 62 (41.3)   
 T3 100 28 (28.0)   
 T4 53 13 (24.5)   
Node status at baseline    0.917 NS
 - 52 18 (34.6)   
 + 251 85 (33.9)   
Histology at baseline    0.263 NS
 Invasive ductal carcinoma 224 82 (36.6)   
 Invasive (mixed) carcinoma 62 17 (27.4)   
 Others 17 4 (23.5)   
Ki-67 expression at baseline    < 0.001 0.001
  < 20% 107 22 (20.6)   
  ≥ 20% 196 81 (41.3)   
sMMP-9 at baseline (ng/ml)    0.519 NS*
 Low (< 505.5) 101 34 (33.7)   
 Intermediate (505.5–712.8) 100 38 (38.0)   
 High (> 712.8) 102 31 (30.4)   
sMMP-9 at surgery (ng/ml)    0.020 0.043*
 Low (< 423.2) 100 42 (42.0)   
 Intermediate (423.2–612.3) 102 37 (36.3)   
 High (> 612.3) 101 24 (23.8)   
sMMP-9 decrease (ng/ml)    < 0.001 0.003*
 Low (< 28.3) 100 24 (24.0)   
 Intermediate (28.3–143.8) 101 29 (28.7)   
 High (> 143.8) 102 50 (49.0)   
Clinical response    0.172 NS
 CR/PR 102 40 (39.2)   
 SD/PD 201 63 (31.3)   
  1. *sMMP-9 was studied in the multivariate analysis as linearly variable